Please Wait...

Clinical Trial Articles

Whether you're interested in the current clinical trial management industry trends or want to know more about the latest FDA requirements, our collection of clinical trial articles will keep you up to date on what's happening now in clinical research news.

Clinical Trial Articles

2017

Essential ToolsCo-authored by Mélanie Bodnar-Wachtel, PhD and Tanja Schubert, PhD

This article is taken from European Biopharmaceutical Review April 2017, pages 34-38. © Samedan Ltd.

2016

Clare Jackson, Utku Ozdemir, Liz Moench.  Take a Chance.  ICT.  February 2016.

Kristin Mauri, PMP, Enterprise Quality Management of Clinical Trials, April 2016.

2014

Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, Langdon RB, Yao S, Lu BD.  A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumuma

Herron D. The New Road of Cardio-Oncology in Clinical Development. Applied Clinical Trials. April 1, 2014.

deVillafranca C, Andrus J. Technology Considerations To Increasing Clinical Trial Efficiencies With Risk-Based Monitoring. Life Science Leader. January 31, 2014.

2013

O'Neal M, Strafaci J, Scarimbolo R, and Van Heertum R. A Paradigm in Evolution. European Pharmaceutical Contractor (EPC) March 2013.

Borradaile K, Duffy K, O'Neal M. A Potential New Approach to Assessing PFS in Solid Tumor Studies. International Clinical Trials, May 2013.

2012

Yu HJ, Miller CG, Flitcraft D. Metrics in Medical Imaging: Changing the Picture. ACRP: The Monitor. August 2012.

2011

Spano Lander A and Lander, Reta C Rupich. No Limits: The Evolution of DXA. International Clinical Trials, February, 2011.

van Meurs P, Miller CG. Image Conscious: New FDA Guidance. Samedan Ltd. 2011 Dec: 24-28.

2010

Borradaile K, Robert F, O'Neal M, Byrne K.

Webber B.

Ahmad H.

2009

Weinstein M. An Albatross and an Opportunity. View on Clinical Operations. 2009 Jun.

2007

Claypool, B.  Functional outsourcing: a better alternative to traditional outsourcing and EDC. Next Generation Pharmaceutical. 2007.

2006

Reiber J, Heyrich G, van Weert A. A Period of Refinement. European Pharmaceutical Contractor (EPC). 2006;100-102.

2004

Miller CG, Noever K.

van Weert A, Reiber J.

van Weert A and Reiber J.

Kradjian S, Baratelle A, Einstein SG, Kaslow DCDevelopment of a Charter for an Endpoint Assessmen

2003

Miller C, Noever K. Scanning data for clinical information. Good Clinical Practices Journal. 2003. 10;9:21-24.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @lauren_chazal: OA is highly prevalent worldwide! Let's work together globally to fight OA... #orasi2017 @bioclinica https://t.co/sAofL…
bioclinica (2 days ago)
Awesome #TYCTWD in our Audubon office yesterday! Great grp of kids.Thanks all for making it a big hit & a day to r… https://t.co/gLZilvN4Wy
bioclinica (2 days ago)
[Fun Friday] When It Comes to Success, Age Really Is Just a Number Via NYT https://t.co/u82mvoYxhg
bioclinica (2 days ago)
RT @eClinical_Jen: Ron Fitzmartin of FDA states "The Reason why the FDA supports standards is to get medical products approved faster" 👍#C…
bioclinica (3 days ago)
RT @eClinical_Jen: Donate your health data to research! Check out the S4S project mentioned by @iamnotthelotus at #CDISCEurope #pharma http…
bioclinica (3 days ago)
RT @lauren_chazal: #oarsi2017 what IS the future of OA? @bioclinica https://t.co/Q9MhW8F50g
bioclinica (3 days ago)

Latest Blogs: